nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyldopa—SLC15A1—Trandolapril—coronary artery disease	0.135	0.21	CbGbCtD
Methyldopa—SLC15A1—Perindopril—coronary artery disease	0.123	0.192	CbGbCtD
Methyldopa—SLC15A1—Enalapril—coronary artery disease	0.102	0.159	CbGbCtD
Methyldopa—SLC15A1—Ramipril—coronary artery disease	0.102	0.159	CbGbCtD
Methyldopa—SLC15A1—Lisinopril—coronary artery disease	0.102	0.159	CbGbCtD
Methyldopa—SLC15A1—Captopril—coronary artery disease	0.0766	0.119	CbGbCtD
Methyldopa—Isoprenaline—MAPK1—coronary artery disease	0.00069	0.118	CrCbGaD
Methyldopa—Isoetarine—ADRB1—coronary artery disease	0.000495	0.0845	CrCbGaD
Methyldopa—Aminosalicylic Acid—MPO—coronary artery disease	0.00046	0.0784	CrCbGaD
Methyldopa—Isoetarine—ADRB2—coronary artery disease	0.000417	0.071	CrCbGaD
Methyldopa—Mesalazine—MPO—coronary artery disease	0.000361	0.0615	CrCbGaD
Methyldopa—Norepinephrine—SLC22A3—coronary artery disease	0.00035	0.0597	CrCbGaD
Methyldopa—Dopamine—SLC22A3—coronary artery disease	0.000326	0.0555	CrCbGaD
Methyldopa—Mesalazine—PPARG—coronary artery disease	0.00032	0.0546	CrCbGaD
Methyldopa—Droxidopa—ADRB1—coronary artery disease	0.000226	0.0386	CrCbGaD
Methyldopa—Dopamine—HTR7—coronary artery disease	0.000207	0.0352	CrCbGaD
Methyldopa—Isoprenaline—ADRB1—coronary artery disease	0.000206	0.0351	CrCbGaD
Methyldopa—Norepinephrine—ADRB1—coronary artery disease	0.000191	0.0325	CrCbGaD
Methyldopa—Droxidopa—ADRB2—coronary artery disease	0.00019	0.0324	CrCbGaD
Methyldopa—Dopamine—ADRB1—coronary artery disease	0.000177	0.0302	CrCbGaD
Methyldopa—Isoprenaline—ADRB2—coronary artery disease	0.000173	0.0295	CrCbGaD
Methyldopa—Epinephrine—ADRB1—coronary artery disease	0.000173	0.0295	CrCbGaD
Methyldopa—Aminosalicylic Acid—PTGS2—coronary artery disease	0.000172	0.0294	CrCbGaD
Methyldopa—Epinephrine—TNF—coronary artery disease	0.000164	0.028	CrCbGaD
Methyldopa—Norepinephrine—ADRB2—coronary artery disease	0.00016	0.0273	CrCbGaD
Methyldopa—Epinephrine—ADRB2—coronary artery disease	0.000145	0.0248	CrCbGaD
Methyldopa—Rash—Acetylsalicylic acid—coronary artery disease	0.000145	0.000569	CcSEcCtD
Methyldopa—Hypersensitivity—Ezetimibe—coronary artery disease	0.000144	0.000569	CcSEcCtD
Methyldopa—Asthenia—Clopidogrel—coronary artery disease	0.000144	0.000568	CcSEcCtD
Methyldopa—Dermatitis—Acetylsalicylic acid—coronary artery disease	0.000144	0.000568	CcSEcCtD
Methyldopa—Skin disorder—Furosemide—coronary artery disease	0.000144	0.000566	CcSEcCtD
Methyldopa—Asthenia—Lovastatin—coronary artery disease	0.000143	0.000564	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Captopril—coronary artery disease	0.000143	0.000562	CcSEcCtD
Methyldopa—Oedema—Losartan—coronary artery disease	0.000143	0.000562	CcSEcCtD
Methyldopa—Infection—Losartan—coronary artery disease	0.000142	0.000558	CcSEcCtD
Methyldopa—Angiopathy—Lisinopril—coronary artery disease	0.000142	0.000558	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Trandolapril—coronary artery disease	0.000142	0.000558	CcSEcCtD
Methyldopa—Mediastinal disorder—Lisinopril—coronary artery disease	0.000141	0.000554	CcSEcCtD
Methyldopa—Paraesthesia—Captopril—coronary artery disease	0.000141	0.000554	CcSEcCtD
Methyldopa—Asthenia—Ezetimibe—coronary artery disease	0.000141	0.000554	CcSEcCtD
Methyldopa—Constipation—Trandolapril—coronary artery disease	0.00014	0.000553	CcSEcCtD
Methyldopa—Nausea—Rosuvastatin—coronary artery disease	0.00014	0.000551	CcSEcCtD
Methyldopa—Diarrhoea—Fenofibrate—coronary artery disease	0.00014	0.000551	CcSEcCtD
Methyldopa—Nervous system disorder—Losartan—coronary artery disease	0.00014	0.000551	CcSEcCtD
Methyldopa—Thrombocytopenia—Losartan—coronary artery disease	0.00014	0.00055	CcSEcCtD
Methyldopa—Constipation—Enalapril—coronary artery disease	0.00014	0.00055	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Telmisartan—coronary artery disease	0.000139	0.000548	CcSEcCtD
Methyldopa—Body temperature increased—Olmesartan—coronary artery disease	0.000139	0.000547	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Perindopril—coronary artery disease	0.000139	0.000546	CcSEcCtD
Methyldopa—Constipation—Telmisartan—coronary artery disease	0.000138	0.000543	CcSEcCtD
Methyldopa—Hypersensitivity—Simvastatin—coronary artery disease	0.000138	0.000542	CcSEcCtD
Methyldopa—Diarrhoea—Clopidogrel—coronary artery disease	0.000138	0.000542	CcSEcCtD
Methyldopa—Asthenia—Eplerenone—coronary artery disease	0.000138	0.000542	CcSEcCtD
Methyldopa—Mental disorder—Lisinopril—coronary artery disease	0.000137	0.000539	CcSEcCtD
Methyldopa—Diarrhoea—Lovastatin—coronary artery disease	0.000137	0.000538	CcSEcCtD
Methyldopa—Paraesthesia—Perindopril—coronary artery disease	0.000137	0.000538	CcSEcCtD
Methyldopa—Nausea—Acetylsalicylic acid—coronary artery disease	0.000136	0.000536	CcSEcCtD
Methyldopa—Body temperature increased—Niacin—coronary artery disease	0.000136	0.000534	CcSEcCtD
Methyldopa—Dizziness—Fenofibrate—coronary artery disease	0.000135	0.000533	CcSEcCtD
Methyldopa—Mesalazine—PTGS2—coronary artery disease	0.000135	0.0231	CrCbGaD
Methyldopa—Leukopenia—Ramipril—coronary artery disease	0.000134	0.000529	CcSEcCtD
Methyldopa—Asthenia—Simvastatin—coronary artery disease	0.000134	0.000528	CcSEcCtD
Methyldopa—Diarrhoea—Ezetimibe—coronary artery disease	0.000134	0.000528	CcSEcCtD
Methyldopa—Constipation—Captopril—coronary artery disease	0.000134	0.000528	CcSEcCtD
Methyldopa—Flatulence—Lisinopril—coronary artery disease	0.000134	0.000528	CcSEcCtD
Methyldopa—Body temperature increased—Pravastatin—coronary artery disease	0.000134	0.000526	CcSEcCtD
Methyldopa—Dizziness—Clopidogrel—coronary artery disease	0.000133	0.000524	CcSEcCtD
Methyldopa—Paraesthesia—Furosemide—coronary artery disease	0.000133	0.000523	CcSEcCtD
Methyldopa—Dizziness—Lovastatin—coronary artery disease	0.000132	0.00052	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Perindopril—coronary artery disease	0.000131	0.000517	CcSEcCtD
Methyldopa—Diarrhoea—Eplerenone—coronary artery disease	0.000131	0.000517	CcSEcCtD
Methyldopa—Constipation—Perindopril—coronary artery disease	0.00013	0.000512	CcSEcCtD
Methyldopa—Vomiting—Fenofibrate—coronary artery disease	0.00013	0.000512	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Losartan—coronary artery disease	0.00013	0.000512	CcSEcCtD
Methyldopa—Hypersensitivity—Valsartan—coronary artery disease	0.00013	0.000512	CcSEcCtD
Methyldopa—Body temperature increased—Trandolapril—coronary artery disease	0.00013	0.000511	CcSEcCtD
Methyldopa—Dizziness—Ezetimibe—coronary artery disease	0.00013	0.00051	CcSEcCtD
Methyldopa—Body temperature increased—Enalapril—coronary artery disease	0.000129	0.000509	CcSEcCtD
Methyldopa—Rash—Fenofibrate—coronary artery disease	0.000129	0.000508	CcSEcCtD
Methyldopa—Dermatitis—Fenofibrate—coronary artery disease	0.000129	0.000508	CcSEcCtD
Methyldopa—Headache—Fenofibrate—coronary artery disease	0.000128	0.000505	CcSEcCtD
Methyldopa—Paraesthesia—Losartan—coronary artery disease	0.000128	0.000505	CcSEcCtD
Methyldopa—Dopamine—CYP2C19—coronary artery disease	0.000128	0.0219	CrCbGaD
Methyldopa—Vomiting—Clopidogrel—coronary artery disease	0.000128	0.000504	CcSEcCtD
Methyldopa—Diarrhoea—Simvastatin—coronary artery disease	0.000128	0.000504	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Furosemide—coronary artery disease	0.000128	0.000503	CcSEcCtD
Methyldopa—Arthralgia—Ramipril—coronary artery disease	0.000128	0.000503	CcSEcCtD
Methyldopa—Myalgia—Ramipril—coronary artery disease	0.000128	0.000503	CcSEcCtD
Methyldopa—Body temperature increased—Telmisartan—coronary artery disease	0.000127	0.000502	CcSEcCtD
Methyldopa—Vomiting—Lovastatin—coronary artery disease	0.000127	0.0005	CcSEcCtD
Methyldopa—Dizziness—Eplerenone—coronary artery disease	0.000127	0.000499	CcSEcCtD
Methyldopa—Rash—Clopidogrel—coronary artery disease	0.000127	0.000499	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Ramipril—coronary artery disease	0.000127	0.000499	CcSEcCtD
Methyldopa—Dermatitis—Clopidogrel—coronary artery disease	0.000127	0.000499	CcSEcCtD
Methyldopa—Asthenia—Valsartan—coronary artery disease	0.000127	0.000499	CcSEcCtD
Methyldopa—Constipation—Furosemide—coronary artery disease	0.000127	0.000498	CcSEcCtD
Methyldopa—Hypersensitivity—Niacin—coronary artery disease	0.000127	0.000498	CcSEcCtD
Methyldopa—Asthenia—Olmesartan—coronary artery disease	0.000126	0.000496	CcSEcCtD
Methyldopa—Headache—Clopidogrel—coronary artery disease	0.000126	0.000496	CcSEcCtD
Methyldopa—Rash—Lovastatin—coronary artery disease	0.000126	0.000496	CcSEcCtD
Methyldopa—Dermatitis—Lovastatin—coronary artery disease	0.000126	0.000496	CcSEcCtD
Methyldopa—Headache—Lovastatin—coronary artery disease	0.000125	0.000493	CcSEcCtD
Methyldopa—Myalgia—Timolol—coronary artery disease	0.000125	0.000491	CcSEcCtD
Methyldopa—Arthralgia—Timolol—coronary artery disease	0.000125	0.000491	CcSEcCtD
Methyldopa—Vomiting—Ezetimibe—coronary artery disease	0.000125	0.000491	CcSEcCtD
Methyldopa—Hypersensitivity—Pravastatin—coronary artery disease	0.000125	0.00049	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Timolol—coronary artery disease	0.000124	0.000488	CcSEcCtD
Methyldopa—Body temperature increased—Captopril—coronary artery disease	0.000124	0.000488	CcSEcCtD
Methyldopa—Dizziness—Simvastatin—coronary artery disease	0.000124	0.000487	CcSEcCtD
Methyldopa—Rash—Ezetimibe—coronary artery disease	0.000124	0.000487	CcSEcCtD
Methyldopa—Dermatitis—Ezetimibe—coronary artery disease	0.000124	0.000486	CcSEcCtD
Methyldopa—Asthenia—Niacin—coronary artery disease	0.000123	0.000485	CcSEcCtD
Methyldopa—Headache—Ezetimibe—coronary artery disease	0.000123	0.000483	CcSEcCtD
Methyldopa—Oedema—Ramipril—coronary artery disease	0.000122	0.000482	CcSEcCtD
Methyldopa—Constipation—Losartan—coronary artery disease	0.000122	0.000481	CcSEcCtD
Methyldopa—Vomiting—Eplerenone—coronary artery disease	0.000122	0.00048	CcSEcCtD
Methyldopa—Leukopenia—Lisinopril—coronary artery disease	0.000122	0.000479	CcSEcCtD
Methyldopa—Nausea—Fenofibrate—coronary artery disease	0.000122	0.000479	CcSEcCtD
Methyldopa—Asthenia—Pravastatin—coronary artery disease	0.000121	0.000477	CcSEcCtD
Methyldopa—Rash—Eplerenone—coronary artery disease	0.000121	0.000476	CcSEcCtD
Methyldopa—Hypersensitivity—Trandolapril—coronary artery disease	0.000121	0.000476	CcSEcCtD
Methyldopa—Dermatitis—Eplerenone—coronary artery disease	0.000121	0.000476	CcSEcCtD
Methyldopa—Diarrhoea—Valsartan—coronary artery disease	0.000121	0.000476	CcSEcCtD
Methyldopa—Hypersensitivity—Enalapril—coronary artery disease	0.00012	0.000474	CcSEcCtD
Methyldopa—Body temperature increased—Perindopril—coronary artery disease	0.00012	0.000474	CcSEcCtD
Methyldopa—Diarrhoea—Olmesartan—coronary artery disease	0.00012	0.000473	CcSEcCtD
Methyldopa—Headache—Eplerenone—coronary artery disease	0.00012	0.000473	CcSEcCtD
Methyldopa—Nervous system disorder—Ramipril—coronary artery disease	0.00012	0.000473	CcSEcCtD
Methyldopa—Thrombocytopenia—Ramipril—coronary artery disease	0.00012	0.000472	CcSEcCtD
Methyldopa—Oedema—Timolol—coronary artery disease	0.00012	0.000471	CcSEcCtD
Methyldopa—Nausea—Clopidogrel—coronary artery disease	0.00012	0.00047	CcSEcCtD
Methyldopa—Skin disorder—Ramipril—coronary artery disease	0.000119	0.000468	CcSEcCtD
Methyldopa—Infection—Timolol—coronary artery disease	0.000119	0.000468	CcSEcCtD
Methyldopa—Vomiting—Simvastatin—coronary artery disease	0.000119	0.000468	CcSEcCtD
Methyldopa—Hypersensitivity—Telmisartan—coronary artery disease	0.000119	0.000468	CcSEcCtD
Methyldopa—Nausea—Lovastatin—coronary artery disease	0.000119	0.000467	CcSEcCtD
Methyldopa—Rash—Simvastatin—coronary artery disease	0.000118	0.000464	CcSEcCtD
Methyldopa—Dermatitis—Simvastatin—coronary artery disease	0.000118	0.000464	CcSEcCtD
Methyldopa—Asthenia—Trandolapril—coronary artery disease	0.000118	0.000464	CcSEcCtD
Methyldopa—Diarrhoea—Niacin—coronary artery disease	0.000117	0.000462	CcSEcCtD
Methyldopa—Nervous system disorder—Timolol—coronary artery disease	0.000117	0.000462	CcSEcCtD
Methyldopa—Asthenia—Enalapril—coronary artery disease	0.000117	0.000462	CcSEcCtD
Methyldopa—Headache—Simvastatin—coronary artery disease	0.000117	0.000461	CcSEcCtD
Methyldopa—Body temperature increased—Furosemide—coronary artery disease	0.000117	0.000461	CcSEcCtD
Methyldopa—Dizziness—Valsartan—coronary artery disease	0.000117	0.00046	CcSEcCtD
Methyldopa—Nausea—Ezetimibe—coronary artery disease	0.000116	0.000458	CcSEcCtD
Methyldopa—Skin disorder—Timolol—coronary artery disease	0.000116	0.000458	CcSEcCtD
Methyldopa—Dizziness—Olmesartan—coronary artery disease	0.000116	0.000457	CcSEcCtD
Methyldopa—Myalgia—Lisinopril—coronary artery disease	0.000116	0.000456	CcSEcCtD
Methyldopa—Arthralgia—Lisinopril—coronary artery disease	0.000116	0.000456	CcSEcCtD
Methyldopa—Asthenia—Telmisartan—coronary artery disease	0.000116	0.000455	CcSEcCtD
Methyldopa—Diarrhoea—Pravastatin—coronary artery disease	0.000116	0.000455	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—coronary artery disease	0.000115	0.000453	CcSEcCtD
Methyldopa—Nausea—Eplerenone—coronary artery disease	0.000114	0.000449	CcSEcCtD
Methyldopa—Dizziness—Niacin—coronary artery disease	0.000114	0.000447	CcSEcCtD
Methyldopa—Body temperature increased—Losartan—coronary artery disease	0.000113	0.000444	CcSEcCtD
Methyldopa—Asthenia—Captopril—coronary artery disease	0.000113	0.000443	CcSEcCtD
Methyldopa—Diarrhoea—Trandolapril—coronary artery disease	0.000112	0.000442	CcSEcCtD
Methyldopa—Vomiting—Valsartan—coronary artery disease	0.000112	0.000442	CcSEcCtD
Methyldopa—Diarrhoea—Enalapril—coronary artery disease	0.000112	0.00044	CcSEcCtD
Methyldopa—Dizziness—Pravastatin—coronary artery disease	0.000112	0.00044	CcSEcCtD
Methyldopa—Vomiting—Olmesartan—coronary artery disease	0.000112	0.00044	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Ramipril—coronary artery disease	0.000112	0.000439	CcSEcCtD
Methyldopa—Rash—Valsartan—coronary artery disease	0.000111	0.000438	CcSEcCtD
Methyldopa—Dermatitis—Valsartan—coronary artery disease	0.000111	0.000438	CcSEcCtD
Methyldopa—Nausea—Simvastatin—coronary artery disease	0.000111	0.000437	CcSEcCtD
Methyldopa—Oedema—Lisinopril—coronary artery disease	0.000111	0.000437	CcSEcCtD
Methyldopa—Rash—Olmesartan—coronary artery disease	0.000111	0.000436	CcSEcCtD
Methyldopa—Dermatitis—Olmesartan—coronary artery disease	0.000111	0.000436	CcSEcCtD
Methyldopa—Headache—Valsartan—coronary artery disease	0.000111	0.000435	CcSEcCtD
Methyldopa—Diarrhoea—Telmisartan—coronary artery disease	0.00011	0.000434	CcSEcCtD
Methyldopa—Infection—Lisinopril—coronary artery disease	0.00011	0.000434	CcSEcCtD
Methyldopa—Headache—Olmesartan—coronary artery disease	0.00011	0.000433	CcSEcCtD
Methyldopa—Paraesthesia—Ramipril—coronary artery disease	0.00011	0.000433	CcSEcCtD
Methyldopa—Asthenia—Perindopril—coronary artery disease	0.000109	0.00043	CcSEcCtD
Methyldopa—Vomiting—Niacin—coronary artery disease	0.000109	0.00043	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Timolol—coronary artery disease	0.000109	0.000429	CcSEcCtD
Methyldopa—Hypersensitivity—Furosemide—coronary artery disease	0.000109	0.000429	CcSEcCtD
Methyldopa—Thrombocytopenia—Lisinopril—coronary artery disease	0.000109	0.000428	CcSEcCtD
Methyldopa—Dizziness—Trandolapril—coronary artery disease	0.000109	0.000427	CcSEcCtD
Methyldopa—Rash—Niacin—coronary artery disease	0.000108	0.000426	CcSEcCtD
Methyldopa—Dermatitis—Niacin—coronary artery disease	0.000108	0.000426	CcSEcCtD
Methyldopa—Dizziness—Enalapril—coronary artery disease	0.000108	0.000426	CcSEcCtD
Methyldopa—Skin disorder—Lisinopril—coronary artery disease	0.000108	0.000425	CcSEcCtD
Methyldopa—Headache—Niacin—coronary artery disease	0.000108	0.000423	CcSEcCtD
Methyldopa—Paraesthesia—Timolol—coronary artery disease	0.000108	0.000423	CcSEcCtD
Methyldopa—Vomiting—Pravastatin—coronary artery disease	0.000107	0.000423	CcSEcCtD
Methyldopa—Diarrhoea—Captopril—coronary artery disease	0.000107	0.000422	CcSEcCtD
Methyldopa—Dizziness—Telmisartan—coronary artery disease	0.000107	0.00042	CcSEcCtD
Methyldopa—Rash—Pravastatin—coronary artery disease	0.000107	0.00042	CcSEcCtD
Methyldopa—Dermatitis—Pravastatin—coronary artery disease	0.000106	0.000419	CcSEcCtD
Methyldopa—Asthenia—Furosemide—coronary artery disease	0.000106	0.000418	CcSEcCtD
Methyldopa—Headache—Pravastatin—coronary artery disease	0.000106	0.000417	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Ramipril—coronary artery disease	0.000106	0.000416	CcSEcCtD
Methyldopa—Hypersensitivity—Losartan—coronary artery disease	0.000105	0.000414	CcSEcCtD
Methyldopa—Nausea—Valsartan—coronary artery disease	0.000105	0.000413	CcSEcCtD
Methyldopa—Constipation—Ramipril—coronary artery disease	0.000105	0.000412	CcSEcCtD
Methyldopa—Nausea—Olmesartan—coronary artery disease	0.000104	0.000411	CcSEcCtD
Methyldopa—Vomiting—Trandolapril—coronary artery disease	0.000104	0.000411	CcSEcCtD
Methyldopa—Diarrhoea—Perindopril—coronary artery disease	0.000104	0.00041	CcSEcCtD
Methyldopa—Vomiting—Enalapril—coronary artery disease	0.000104	0.000409	CcSEcCtD
Methyldopa—Dizziness—Captopril—coronary artery disease	0.000104	0.000408	CcSEcCtD
Methyldopa—Rash—Trandolapril—coronary artery disease	0.000104	0.000407	CcSEcCtD
Methyldopa—Dermatitis—Trandolapril—coronary artery disease	0.000103	0.000407	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Timolol—coronary artery disease	0.000103	0.000407	CcSEcCtD
Methyldopa—Rash—Enalapril—coronary artery disease	0.000103	0.000406	CcSEcCtD
Methyldopa—Dermatitis—Enalapril—coronary artery disease	0.000103	0.000405	CcSEcCtD
Methyldopa—Headache—Trandolapril—coronary artery disease	0.000103	0.000405	CcSEcCtD
Methyldopa—Vomiting—Telmisartan—coronary artery disease	0.000103	0.000404	CcSEcCtD
Methyldopa—Asthenia—Losartan—coronary artery disease	0.000102	0.000403	CcSEcCtD
Methyldopa—Headache—Enalapril—coronary artery disease	0.000102	0.000403	CcSEcCtD
Methyldopa—Nausea—Niacin—coronary artery disease	0.000102	0.000401	CcSEcCtD
Methyldopa—Rash—Telmisartan—coronary artery disease	0.000102	0.0004	CcSEcCtD
Methyldopa—Dermatitis—Telmisartan—coronary artery disease	0.000102	0.0004	CcSEcCtD
Methyldopa—Diarrhoea—Furosemide—coronary artery disease	0.000101	0.000399	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Lisinopril—coronary artery disease	0.000101	0.000398	CcSEcCtD
Methyldopa—Headache—Telmisartan—coronary artery disease	0.000101	0.000398	CcSEcCtD
Methyldopa—Dizziness—Perindopril—coronary artery disease	0.000101	0.000396	CcSEcCtD
Methyldopa—Nausea—Pravastatin—coronary artery disease	0.0001	0.000395	CcSEcCtD
Methyldopa—Paraesthesia—Lisinopril—coronary artery disease	9.97e-05	0.000392	CcSEcCtD
Methyldopa—Vomiting—Captopril—coronary artery disease	9.97e-05	0.000392	CcSEcCtD
Methyldopa—Rash—Captopril—coronary artery disease	9.89e-05	0.000389	CcSEcCtD
Methyldopa—Dermatitis—Captopril—coronary artery disease	9.88e-05	0.000389	CcSEcCtD
Methyldopa—Headache—Captopril—coronary artery disease	9.82e-05	0.000387	CcSEcCtD
Methyldopa—Dizziness—Furosemide—coronary artery disease	9.79e-05	0.000385	CcSEcCtD
Methyldopa—Diarrhoea—Losartan—coronary artery disease	9.77e-05	0.000385	CcSEcCtD
Methyldopa—Nausea—Trandolapril—coronary artery disease	9.75e-05	0.000384	CcSEcCtD
Methyldopa—Nausea—Enalapril—coronary artery disease	9.71e-05	0.000382	CcSEcCtD
Methyldopa—Vomiting—Perindopril—coronary artery disease	9.68e-05	0.000381	CcSEcCtD
Methyldopa—Body temperature increased—Ramipril—coronary artery disease	9.68e-05	0.000381	CcSEcCtD
Methyldopa—Rash—Perindopril—coronary artery disease	9.6e-05	0.000378	CcSEcCtD
Methyldopa—Dermatitis—Perindopril—coronary artery disease	9.59e-05	0.000377	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Lisinopril—coronary artery disease	9.59e-05	0.000377	CcSEcCtD
Methyldopa—Nausea—Telmisartan—coronary artery disease	9.58e-05	0.000377	CcSEcCtD
Methyldopa—Headache—Perindopril—coronary artery disease	9.54e-05	0.000375	CcSEcCtD
Methyldopa—Constipation—Lisinopril—coronary artery disease	9.5e-05	0.000374	CcSEcCtD
Methyldopa—Body temperature increased—Timolol—coronary artery disease	9.46e-05	0.000372	CcSEcCtD
Methyldopa—Dizziness—Losartan—coronary artery disease	9.44e-05	0.000372	CcSEcCtD
Methyldopa—Vomiting—Furosemide—coronary artery disease	9.41e-05	0.00037	CcSEcCtD
Methyldopa—Rash—Furosemide—coronary artery disease	9.33e-05	0.000367	CcSEcCtD
Methyldopa—Dermatitis—Furosemide—coronary artery disease	9.32e-05	0.000367	CcSEcCtD
Methyldopa—Nausea—Captopril—coronary artery disease	9.32e-05	0.000367	CcSEcCtD
Methyldopa—Headache—Furosemide—coronary artery disease	9.27e-05	0.000365	CcSEcCtD
Methyldopa—Vomiting—Losartan—coronary artery disease	9.08e-05	0.000357	CcSEcCtD
Methyldopa—Nausea—Perindopril—coronary artery disease	9.04e-05	0.000356	CcSEcCtD
Methyldopa—Hypersensitivity—Ramipril—coronary artery disease	9.02e-05	0.000355	CcSEcCtD
Methyldopa—Rash—Losartan—coronary artery disease	9.01e-05	0.000354	CcSEcCtD
Methyldopa—Dermatitis—Losartan—coronary artery disease	9e-05	0.000354	CcSEcCtD
Methyldopa—Headache—Losartan—coronary artery disease	8.95e-05	0.000352	CcSEcCtD
Methyldopa—Hypersensitivity—Timolol—coronary artery disease	8.82e-05	0.000347	CcSEcCtD
Methyldopa—Nausea—Furosemide—coronary artery disease	8.79e-05	0.000346	CcSEcCtD
Methyldopa—Asthenia—Ramipril—coronary artery disease	8.79e-05	0.000346	CcSEcCtD
Methyldopa—Body temperature increased—Lisinopril—coronary artery disease	8.78e-05	0.000346	CcSEcCtD
Methyldopa—Asthenia—Timolol—coronary artery disease	8.59e-05	0.000338	CcSEcCtD
Methyldopa—Nausea—Losartan—coronary artery disease	8.48e-05	0.000334	CcSEcCtD
Methyldopa—Diarrhoea—Ramipril—coronary artery disease	8.38e-05	0.00033	CcSEcCtD
Methyldopa—Diarrhoea—Timolol—coronary artery disease	8.19e-05	0.000322	CcSEcCtD
Methyldopa—Hypersensitivity—Lisinopril—coronary artery disease	8.18e-05	0.000322	CcSEcCtD
Methyldopa—Dizziness—Ramipril—coronary artery disease	8.1e-05	0.000319	CcSEcCtD
Methyldopa—Asthenia—Lisinopril—coronary artery disease	7.97e-05	0.000314	CcSEcCtD
Methyldopa—Dizziness—Timolol—coronary artery disease	7.92e-05	0.000312	CcSEcCtD
Methyldopa—Vomiting—Ramipril—coronary artery disease	7.79e-05	0.000306	CcSEcCtD
Methyldopa—Rash—Ramipril—coronary artery disease	7.72e-05	0.000304	CcSEcCtD
Methyldopa—Dermatitis—Ramipril—coronary artery disease	7.71e-05	0.000304	CcSEcCtD
Methyldopa—Headache—Ramipril—coronary artery disease	7.67e-05	0.000302	CcSEcCtD
Methyldopa—Vomiting—Timolol—coronary artery disease	7.61e-05	0.0003	CcSEcCtD
Methyldopa—Diarrhoea—Lisinopril—coronary artery disease	7.6e-05	0.000299	CcSEcCtD
Methyldopa—Rash—Timolol—coronary artery disease	7.55e-05	0.000297	CcSEcCtD
Methyldopa—Dermatitis—Timolol—coronary artery disease	7.54e-05	0.000297	CcSEcCtD
Methyldopa—Headache—Timolol—coronary artery disease	7.5e-05	0.000295	CcSEcCtD
Methyldopa—Dizziness—Lisinopril—coronary artery disease	7.34e-05	0.000289	CcSEcCtD
Methyldopa—Nausea—Ramipril—coronary artery disease	7.27e-05	0.000286	CcSEcCtD
Methyldopa—Nausea—Timolol—coronary artery disease	7.11e-05	0.00028	CcSEcCtD
Methyldopa—Vomiting—Lisinopril—coronary artery disease	7.06e-05	0.000278	CcSEcCtD
Methyldopa—Rash—Lisinopril—coronary artery disease	7e-05	0.000276	CcSEcCtD
Methyldopa—Dermatitis—Lisinopril—coronary artery disease	7e-05	0.000275	CcSEcCtD
Methyldopa—Headache—Lisinopril—coronary artery disease	6.96e-05	0.000274	CcSEcCtD
Methyldopa—Nausea—Lisinopril—coronary artery disease	6.6e-05	0.00026	CcSEcCtD
Methyldopa—ADRA2A—Metabolism—LPA—coronary artery disease	1.9e-05	0.000194	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PLCB1—coronary artery disease	1.89e-05	0.000193	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—APOA1—coronary artery disease	1.89e-05	0.000193	CbGpPWpGaD
Methyldopa—DDC—Metabolism—POMC—coronary artery disease	1.88e-05	0.000192	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PGF—coronary artery disease	1.87e-05	0.000191	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PPBP—coronary artery disease	1.87e-05	0.000191	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—EDNRA—coronary artery disease	1.87e-05	0.000191	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—coronary artery disease	1.86e-05	0.00019	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—ADRB1—coronary artery disease	1.86e-05	0.00019	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—MAPK14—coronary artery disease	1.86e-05	0.00019	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—HTR7—coronary artery disease	1.85e-05	0.000189	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PLCB3—coronary artery disease	1.84e-05	0.000188	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—DVL1—coronary artery disease	1.84e-05	0.000188	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ITGA2B—coronary artery disease	1.84e-05	0.000188	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—TGFB1—coronary artery disease	1.83e-05	0.000187	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—POMC—coronary artery disease	1.83e-05	0.000187	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—APOA5—coronary artery disease	1.83e-05	0.000186	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—FN1—coronary artery disease	1.8e-05	0.000184	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—F2—coronary artery disease	1.8e-05	0.000184	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—MAPK1—coronary artery disease	1.8e-05	0.000184	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CCL2—coronary artery disease	1.79e-05	0.000183	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—P4HB—coronary artery disease	1.79e-05	0.000183	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GHR—coronary artery disease	1.79e-05	0.000182	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—OPRD1—coronary artery disease	1.79e-05	0.000182	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCL4—coronary artery disease	1.79e-05	0.000182	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—NOS2—coronary artery disease	1.78e-05	0.000182	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—KNG1—coronary artery disease	1.76e-05	0.00018	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PLA2G1B—coronary artery disease	1.76e-05	0.000179	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—BDKRB2—coronary artery disease	1.76e-05	0.000179	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CXCL12—coronary artery disease	1.76e-05	0.000179	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AGTR1—coronary artery disease	1.75e-05	0.000179	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PLCB1—coronary artery disease	1.72e-05	0.000175	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ALB—coronary artery disease	1.72e-05	0.000175	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TLE4—coronary artery disease	1.71e-05	0.000175	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MEF2A—coronary artery disease	1.71e-05	0.000175	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CXCL10—coronary artery disease	1.71e-05	0.000175	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PPARG—coronary artery disease	1.7e-05	0.000173	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—HTR7—coronary artery disease	1.68e-05	0.000172	CbGpPWpGaD
Methyldopa—COMT—Metabolism—POMC—coronary artery disease	1.67e-05	0.000171	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—APOA2—coronary artery disease	1.67e-05	0.00017	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—ADRB2—coronary artery disease	1.66e-05	0.000169	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—VCAN—coronary artery disease	1.66e-05	0.000169	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AVPR1A—coronary artery disease	1.65e-05	0.000168	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ALDOA—coronary artery disease	1.64e-05	0.000168	CbGpPWpGaD
Methyldopa—DDC—Metabolism—NOS3—coronary artery disease	1.64e-05	0.000168	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PRKCE—coronary artery disease	1.64e-05	0.000167	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—KNG1—coronary artery disease	1.6e-05	0.000163	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—DCN—coronary artery disease	1.6e-05	0.000163	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—UTS2—coronary artery disease	1.59e-05	0.000163	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AGTR1—coronary artery disease	1.59e-05	0.000162	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—IGF1—coronary artery disease	1.58e-05	0.000161	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—PIK3CA—coronary artery disease	1.56e-05	0.000159	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NR4A1—coronary artery disease	1.56e-05	0.000159	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CXCL10—coronary artery disease	1.55e-05	0.000158	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ALDH2—coronary artery disease	1.55e-05	0.000158	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HDAC9—coronary artery disease	1.54e-05	0.000157	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PLCB3—coronary artery disease	1.54e-05	0.000157	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—P2RY12—coronary artery disease	1.54e-05	0.000157	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CX3CR1—coronary artery disease	1.53e-05	0.000156	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CASR—coronary artery disease	1.53e-05	0.000156	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ALB—coronary artery disease	1.52e-05	0.000156	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—LIPC—coronary artery disease	1.51e-05	0.000154	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—HBA1—coronary artery disease	1.51e-05	0.000154	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3C2A—coronary artery disease	1.51e-05	0.000154	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP2C19—coronary artery disease	1.51e-05	0.000154	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—ADRB2—coronary artery disease	1.51e-05	0.000154	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—APOC3—coronary artery disease	1.5e-05	0.000153	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PTGS2—coronary artery disease	1.5e-05	0.000153	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—SERPINE1—coronary artery disease	1.5e-05	0.000153	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CX3CL1—coronary artery disease	1.5e-05	0.000153	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—BDKRB1—coronary artery disease	1.5e-05	0.000153	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—P4HB—coronary artery disease	1.5e-05	0.000153	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GNA12—coronary artery disease	1.5e-05	0.000153	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—ALB—coronary artery disease	1.49e-05	0.000153	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—LDLR—coronary artery disease	1.49e-05	0.000153	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PRKCE—coronary artery disease	1.49e-05	0.000152	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—EDN1—coronary artery disease	1.48e-05	0.000151	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTT1—coronary artery disease	1.48e-05	0.000151	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SLC9A1—coronary artery disease	1.48e-05	0.000151	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CCL5—coronary artery disease	1.47e-05	0.00015	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PPP3R1—coronary artery disease	1.47e-05	0.00015	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CETP—coronary artery disease	1.46e-05	0.000149	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GCLC—coronary artery disease	1.46e-05	0.000149	CbGpPWpGaD
Methyldopa—COMT—Metabolism—NOS3—coronary artery disease	1.46e-05	0.000149	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ADM—coronary artery disease	1.46e-05	0.000149	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CSF2—coronary artery disease	1.45e-05	0.000148	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SDC1—coronary artery disease	1.44e-05	0.000147	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—NOS3—coronary artery disease	1.43e-05	0.000146	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PDE4B—coronary artery disease	1.42e-05	0.000145	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CYBB—coronary artery disease	1.42e-05	0.000145	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CXCL8—coronary artery disease	1.42e-05	0.000145	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—MMP3—coronary artery disease	1.42e-05	0.000145	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—JAK2—coronary artery disease	1.39e-05	0.000142	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PSMB5—coronary artery disease	1.36e-05	0.000139	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PSMA6—coronary artery disease	1.36e-05	0.000139	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—EDN1—coronary artery disease	1.35e-05	0.000138	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CCL5—coronary artery disease	1.34e-05	0.000136	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PTGS2—coronary artery disease	1.33e-05	0.000136	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CTGF—coronary artery disease	1.33e-05	0.000136	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PRKCD—coronary artery disease	1.33e-05	0.000135	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GOT2—coronary artery disease	1.32e-05	0.000135	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—HMGCR—coronary artery disease	1.32e-05	0.000135	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CSF2—coronary artery disease	1.32e-05	0.000134	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCR3—coronary artery disease	1.3e-05	0.000133	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—HTR2A—coronary artery disease	1.3e-05	0.000132	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—C3—coronary artery disease	1.3e-05	0.000132	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CRK—coronary artery disease	1.28e-05	0.000131	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—AKT1—coronary artery disease	1.28e-05	0.00013	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SH2B3—coronary artery disease	1.26e-05	0.000129	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—VWF—coronary artery disease	1.26e-05	0.000129	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ATP2A2—coronary artery disease	1.26e-05	0.000129	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—APOC3—coronary artery disease	1.26e-05	0.000128	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—LDLR—coronary artery disease	1.25e-05	0.000128	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AGT—coronary artery disease	1.23e-05	0.000126	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PPP2CA—coronary artery disease	1.23e-05	0.000125	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CXCL2—coronary artery disease	1.22e-05	0.000125	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCL3—coronary artery disease	1.22e-05	0.000125	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PLCB1—coronary artery disease	1.21e-05	0.000124	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—F2R—coronary artery disease	1.21e-05	0.000123	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SDC1—coronary artery disease	1.21e-05	0.000123	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PRKCD—coronary artery disease	1.2e-05	0.000123	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FGB—coronary artery disease	1.18e-05	0.000121	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—HTR2A—coronary artery disease	1.18e-05	0.00012	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—C3—coronary artery disease	1.18e-05	0.00012	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ABCA1—coronary artery disease	1.18e-05	0.00012	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EDNRB—coronary artery disease	1.17e-05	0.000119	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—THBS1—coronary artery disease	1.15e-05	0.000118	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PSMB5—coronary artery disease	1.14e-05	0.000116	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PSMA6—coronary artery disease	1.14e-05	0.000116	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GOT1—coronary artery disease	1.14e-05	0.000116	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GGT1—coronary artery disease	1.14e-05	0.000116	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—F2—coronary artery disease	1.14e-05	0.000116	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AGT—coronary artery disease	1.12e-05	0.000114	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EDNRA—coronary artery disease	1.1e-05	0.000113	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CYBA—coronary artery disease	1.1e-05	0.000112	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ADRB1—coronary artery disease	1.1e-05	0.000112	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—DUSP6—coronary artery disease	1.09e-05	0.000112	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PLAT—coronary artery disease	1.08e-05	0.00011	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—BDKRB2—coronary artery disease	1.04e-05	0.000106	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CXCL12—coronary artery disease	1.04e-05	0.000106	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—POMC—coronary artery disease	1.04e-05	0.000106	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—F2—coronary artery disease	1.03e-05	0.000105	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—VEGFA—coronary artery disease	1.03e-05	0.000105	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IL6ST—coronary artery disease	1.03e-05	0.000105	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTP1—coronary artery disease	1.02e-05	0.000104	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—JUNB—coronary artery disease	1.02e-05	0.000104	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PLCB1—coronary artery disease	1.01e-05	0.000104	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PPARGC1A—coronary artery disease	1.01e-05	0.000104	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—HMOX1—coronary artery disease	1.01e-05	0.000103	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CAT—coronary artery disease	9.96e-06	0.000102	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HTR7—coronary artery disease	9.94e-06	0.000101	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—APOB—coronary artery disease	9.67e-06	9.87e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ITGAV—coronary artery disease	9.47e-06	9.67e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—TGFB1—coronary artery disease	9.45e-06	9.65e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KNG1—coronary artery disease	9.44e-06	9.64e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—POMC—coronary artery disease	9.41e-06	9.61e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CREB1—coronary artery disease	9.41e-06	9.61e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTM1—coronary artery disease	9.4e-06	9.6e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AGTR1—coronary artery disease	9.38e-06	9.58e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—MAPK1—coronary artery disease	9.27e-06	9.47e-05	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3CA—coronary artery disease	9.24e-06	9.44e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—LPL—coronary artery disease	9.23e-06	9.43e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CCL2—coronary artery disease	9.21e-06	9.4e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IL6R—coronary artery disease	9.18e-06	9.37e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CXCL10—coronary artery disease	9.17e-06	9.36e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PLG—coronary artery disease	9.14e-06	9.34e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GPX1—coronary artery disease	9.01e-06	9.2e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ADRB2—coronary artery disease	8.9e-06	9.09e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PRKCE—coronary artery disease	8.79e-06	8.97e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—JAK2—coronary artery disease	8.78e-06	8.97e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CD36—coronary artery disease	8.77e-06	8.96e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SOCS1—coronary artery disease	8.77e-06	8.95e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—S100B—coronary artery disease	8.75e-06	8.93e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PPP2CA—coronary artery disease	8.66e-06	8.84e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SOCS3—coronary artery disease	8.66e-06	8.84e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KITLG—coronary artery disease	8.56e-06	8.74e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TGFBR2—coronary artery disease	8.56e-06	8.74e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—STAT5A—coronary artery disease	8.36e-06	8.54e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MMP3—coronary artery disease	8.36e-06	8.54e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—MTHFR—coronary artery disease	8.31e-06	8.49e-05	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CA—coronary artery disease	8.21e-06	8.38e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—APOB—coronary artery disease	8.08e-06	8.25e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CA—coronary artery disease	8.05e-06	8.21e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CXCL8—coronary artery disease	8.01e-06	8.18e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—JAK2—coronary artery disease	7.97e-06	8.14e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EDN1—coronary artery disease	7.96e-06	8.12e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—AGT—coronary artery disease	7.9e-06	8.06e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCL5—coronary artery disease	7.89e-06	8.06e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FGF1—coronary artery disease	7.78e-06	7.94e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CSF2—coronary artery disease	7.78e-06	7.94e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—APOE—coronary artery disease	7.74e-06	7.9e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—LPL—coronary artery disease	7.72e-06	7.88e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MEF2C—coronary artery disease	7.65e-06	7.81e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RPS6KB1—coronary artery disease	7.65e-06	7.81e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—APOA1—coronary artery disease	7.65e-06	7.81e-05	CbGpPWpGaD
Methyldopa—DDC—Metabolism—AKT1—coronary artery disease	7.55e-06	7.71e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ITGB3—coronary artery disease	7.45e-06	7.61e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CXCL8—coronary artery disease	7.28e-06	7.43e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PPP2CA—coronary artery disease	7.24e-06	7.39e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PRKCD—coronary artery disease	7.11e-06	7.26e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HTR2A—coronary artery disease	6.96e-06	7.11e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—C3—coronary artery disease	6.95e-06	7.1e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PPARG—coronary artery disease	6.74e-06	6.88e-05	CbGpPWpGaD
Methyldopa—COMT—Metabolism—AKT1—coronary artery disease	6.7e-06	6.85e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—POMC—coronary artery disease	6.65e-06	6.79e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HIF1A—coronary artery disease	6.63e-06	6.77e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AGT—coronary artery disease	6.6e-06	6.74e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—AKT1—coronary artery disease	6.57e-06	6.71e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—APOE—coronary artery disease	6.47e-06	6.61e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—LEP—coronary artery disease	6.47e-06	6.61e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—APOA1—coronary artery disease	6.4e-06	6.53e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KDR—coronary artery disease	6.34e-06	6.47e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MAPK14—coronary artery disease	6.3e-06	6.43e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ESR1—coronary artery disease	6.18e-06	6.31e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—F2—coronary artery disease	6.1e-06	6.23e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FN1—coronary artery disease	6.1e-06	6.23e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IL6ST—coronary artery disease	6.08e-06	6.2e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ALB—coronary artery disease	6.06e-06	6.19e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NFKBIA—coronary artery disease	6.03e-06	6.16e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KIT—coronary artery disease	5.84e-06	5.96e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—NOS3—coronary artery disease	5.8e-06	5.92e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GSK3B—coronary artery disease	5.6e-06	5.72e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—POMC—coronary artery disease	5.56e-06	5.67e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CREB1—coronary artery disease	5.56e-06	5.67e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCL2—coronary artery disease	5.44e-06	5.55e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IL6R—coronary artery disease	5.42e-06	5.54e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IGF1—coronary artery disease	5.35e-06	5.46e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—MAPK1—coronary artery disease	5.32e-06	5.43e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PTGS2—coronary artery disease	5.3e-06	5.41e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CA—coronary artery disease	5.08e-06	5.19e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SERPINE1—coronary artery disease	5.08e-06	5.18e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FGF2—coronary artery disease	4.91e-06	5.02e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NOS3—coronary artery disease	4.85e-06	4.95e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—JAK2—coronary artery disease	4.71e-06	4.81e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CA—coronary artery disease	4.62e-06	4.71e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CXCL8—coronary artery disease	4.3e-06	4.39e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AKT1—coronary artery disease	4.15e-06	4.24e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CASP3—coronary artery disease	4.12e-06	4.2e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IL6—coronary artery disease	4.09e-06	4.17e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCND1—coronary artery disease	4.01e-06	4.09e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MMP9—coronary artery disease	3.89e-06	3.97e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AKT1—coronary artery disease	3.77e-06	3.85e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—VEGFA—coronary artery disease	3.49e-06	3.57e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CA—coronary artery disease	3.26e-06	3.33e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TGFB1—coronary artery disease	3.21e-06	3.27e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MAPK1—coronary artery disease	3.14e-06	3.21e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CA—coronary artery disease	2.73e-06	2.78e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—AKT1—coronary artery disease	2.66e-06	2.72e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IL6—coronary artery disease	2.42e-06	2.47e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AKT1—coronary artery disease	2.23e-06	2.27e-05	CbGpPWpGaD
